Predictive Oncology Inc.

Before we begin, let me quickly remind you that during the course of this presentation, the company will make forward looking statements. We caution you that any statement that is not a statement of historical fact is a forward looking statement. This includes remarks about the company's projections, expectations, plans, beliefs, and future performance, all of which constitute forward-looking statements for the purpose of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. These statements are based on judgment and analysis as of the date of this presentation and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The company cannot guarantee the accuracy, completeness, or reliability of statements made by third parties or advisors in this presentation, nor can it assure that any expectations, forecasts, or outcomes expressed by third parties or advisors will materialize. The risks and uncertainties associated with the forward-looking statements made in this presentation and webcast are described in the company's public periodic filings with the SEC. Except as required by law, the company assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so. The slides presented in this presentation can be accessed via the investors page of our website.

Good morning, everyone, and welcome to Predictive Oncology's Q3 financial results and business update presentation, which will include an overview of our latest digital asset investment in Aether's ATH token aimed at creating the world's first strategic compute reserve. This investment represents a new business line for predictive oncology through which we believe we will be able to utilize ATH for revenue generating purposes. On September 29th, 2025, we launched the Digital Asset Treasury, focused on Aether's ATH token, tokens that not only power Aether's AI infrastructure, but also our ability to directly benefit from the active digital asset management of their AI infrastructure. This is both relevant and important because, as we have learned, one of the biggest barriers to accelerating AI-driven medical research and discovery is no longer just about good science, but access to reliable and affordable computing power. A growing constraint on innovation in drug discovery or personalized medicine isn't just about the science itself. but the infrastructure required to perfect the computational models and develop the AI methodologies that unlock the science. By recognizing this challenge, we believe that we have strategically positioned ourselves with Ather to address our own future infrastructure needs while investing in an enabling technology that has the potential to unlock the next decade of discovery and innovation, not just in healthcare, but across multiple industries. Our plan is to turn Aether tokens into graphic processing units or GPUs via the Aether partnership and network and GPUs into revenue. And today's deck will show you exactly how we plan to generate cashflow while supporting the AI compute ecosystem. But first let's start with the agenda so that everyone knows what to expect from today's presentation. In addition to what I've already said, I will provide you with a brief company update, followed by a financial report by our CFO, Josh Blatcher. Then we'll move into our new digital asset treasury business and our vision for the ATH token utilization by Tom McLaughlin, who is our chief investment officer, followed by Kyle Okamoto, a member of Predictive Oncology's crypto advisory board. Kyle will do a deep dive into how we plan to leverage our strategic compute reserve to satisfy expertise, market demand, and generate revenue. As I said in my opening remarks, we were very excited to announce this past September that we have initiated a digital asset treasury strategy focused on the Aether ecosystem and its native ATH token. While certainly not the first company to initiate additional assets treasury strategy, Predictive Oncology's investment in ATH goes well beyond a strategy of simply holding digital currencies in our treasury with the goal of enhancing short-term returns. Although this is certainly one very important aspect of the initiative. What really differentiates our digital asset strategy is that by being a participant on the Aether ecosystem, we can play a direct role in expanding access to high performance AI infrastructure and significantly lowering costs as compared to the big cloud providers. This represents a new potential revenue stream that we believe will translate into significant long-term value for the company and our shareholders. The growth and demand for AI compute power cannot be overstated. And numerous recent reports have indicated that this demand is rapidly outpacing infrastructure supply. In fact, one report by Citigroup estimates that AI infrastructure spending will reach $2.8 trillion globally by 2029. We believe our digital asset strategy will allow us to be a beneficiary of this anticipated growth. As a company that has relied on AI to drive our drug and biomarker discovery business, we are well aware of the potential bottleneck that can be created when the availability of AI infrastructure cannot keep pace with global demand, or when the cost is prohibitively expensive. We believe this limits breakthrough innovation, not just in healthcare, but across all sectors. Through this investment in ATH, Predictive Oncology has established the world's first strategic compute reserve, aiming to purchase GPU compute on the Aether network to help democratize access to AI broadly, while we believe we'll address the rapidly growing need for advanced computing power. This is an important event in our company's history, and I am excited about the opportunity that this represents. At this point, I will turn the call over to Josh Blatcher, our CFO, for view of our third quarter financial performance. Josh?

Thank you, Raymond. Before digging into the financials, I would like to point out that both our balance sheet and P&L this quarter include some complex and highly unusual effects of the private placement entered into on September 29th to support our new digital asset treasury strategy. They both include transient entries necessitated simply because of the timing of the closing of the transaction. As you all know, in September, the company carried out two private financing deals to support its treasury strategy, one using cash and the other using cryptocurrency, in particular, Aether tokens or ATH. BULQ became legally effective on September 29th, but closed on October 7th. when the company received $50.8 million in cash and $292.7 million worth of ATH tokens, issuing shares and pre-funded warrants in return. The cash deal or cash SPA was relatively straightforward. On September 29th, the company agreed to issue a fixed number of its shares and pre-funded warrants to investors in exchange for a fixed amount of cash from the investors. The only variable that changed between the deal execution on September 29th and closing on October 7th was the company's stock price, which allows for equity classification under U.S. GAAP and no accounting event to be recorded as of September 29th or September 30th. The crypto deal, or the crypto SPA, involved a more complex value exchange. The company agreed to issue a fixed number of pre-funded warrants in exchange for a fixed number of ATH tokens based on an ATH market price determined on September 26th. The market value of that fixed number of ATH tokens fluctuated between the pricing on September 26th and the close of the third quarter on September 30th and continued to fluctuate until closing on September 7th. As a result, the economic value of the company and investors changed between September 29th and the close of the third quarter on September 30th. Because the economic value changed due to the variable not directly related to the company's own equity, U.S. GAAP requires the contract to be accounted for as a derivative liability at fair value through earnings. The liability was recorded at fair value when the contract took effect on September 29th. then remeasured on September 30th for the quarter end, and finally again on October 7th at the settlement to reflect the fair value of the underlying ATH contributed and the pre-funded warrants as of that date. A Monte Carlo simulation was used to model expected price changes in both ATH and the company's stock price over the short period to calculate gains and losses. When the deal closed on October 7th, the derivative liability was de-recognized and the ATH tokens were recorded as assets while the pre-funded warrants were recorded as equity. The ultimate impact on the P&L will be an entry to earnings reflecting the ultimate change in the relative market value of what investors contributed or ATH tokens versus what they received, pre-funded warrants to purchase the company's common stock. As a result of the foregoing, the financial statements as of 9-30-25 are not indicative of the company's underlying cash position or financial performance. I will call out a few such entries in this review. We concluded the third quarter of 2025 with 182,000 in cash and cash equivalents compared to 612,000 as of December 31st, 2024. Again, due to the derivative liability of 74 million related to the securities purchase contract Supporting the initiation of our digital asset tragedy strategy, stockholders' equity of $77 million was compared to the stockholders' deficit of $203,000 as of December 31, 2024. Our net loss for the third quarter of 2025 was $77.7 million as compared to $3.1 million for the third quarter of September 30, 2024. Again, the significant loss for the third quarter of 2025 was a direct result of the $74.4 million loss on remeasurement of the derivative liability, which was a non-cash charge. Our revenue of 3.6 thousand in the third quarter ended September 30, 2025 was largely unchanged from revenue of 3.9 thousand in the comparable period in 2024. General and administrative expenses of 2.6 million in the three months ended September 30, 2025 was compared to 1.5 billion in the comparable period in 2024. and primarily consists of professional and consulting fees. Operating expenses to operations and R&D were 529,000 for the third quarter of 2025 as compared to 535,000 for the corresponding quarter in 2024. Operating expenses to sales and marketing were $133,000 for the third quarter of 2025 as compared to $73,000 for the corresponding quarter in 2024. Importantly, on our statement of cash flows, the cash flow used for operations was $5.9 million for the nine months ended September 30, 2025 versus $8.0 million for the corresponding period in 2024. The reduction of $2.1 million during the period, or 26%, illustrates how significant our cost reduction initiatives have been and how the non-cash loss on a remeasurement of their derivative liability skews the P&L. The monthly burn implied by the statement of cash flows averages to $650. 56,000. This concludes the financial overview. I will now like to turn the call over to Tom McLaughlin, our new chief investment officer, to walk through our investment strategy. Tom? Thank you, Josh.